Physician profile
Saud Butt
NPI 1063600328
$1,176.13
in general payments reported to CMS, 2019-2025
17 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2022: $20.03 · 2023: $345 · 2024: $218 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $185.23 | 2019-2023 | |
| Nxstage Medical, INC. | $160.24 | 2022-2023 | Nxstage System One, Nxstage Cartridge Express, Liberty Select Cycler |
| Travere Therapeutics, INC. | $149.25 | 2023-2025 | Filspari |
| Baxter Healthcare | $115.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $102.73 | 2024-2025 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.94 | 2024 | |
| Mallinckrodt Hospital Products INC. | $83.01 | 2023 | Terlivaz |
| Calliditas Therapeutics US INC. | $54.06 | 2023-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $48.60 | 2019 | |
| Ardelyx, INC. | $35.99 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.47 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $28.81 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.93 | 2025 | |
| Glaxosmithkline, LLC. | $17.20 | 2025 | Benlysta |
| Fresenius USA Marketing, INC. | $15.14 | 2024 | Nxstage Cartridge Express, Nxstage System One |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.40 | 2025 | Farxiga |
| Opko Pharmaceuticals, LLC | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saud Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.